Keyphrases
Poor Survival
100%
Diffuse Large B-cell Lymphoma (DLBCL)
100%
Melastatin
100%
Activated B Cells
100%
TRP Channels
100%
Cell-like
21%
Overall Survival
21%
Nonmalignant
14%
R-CHOP
14%
Transcript Level
7%
Non-germinal Centre
7%
Normal B Cells
7%
Protein Expression
7%
Microarray Data
7%
Germinal Center B
7%
Clinical Parameters
7%
Ion Channels
7%
Protein Expression Pattern
7%
Lymphoma Subtype
7%
Multivariate Analysis
7%
Publicly Available
7%
Prednisone
7%
Eastern Cooperative Oncology Group
7%
Human Tissue
7%
Demographic Parameters
7%
Lymphoma Patients
7%
Tonsil
7%
Immunohistochemical Analysis
7%
Lactate Dehydrogenase
7%
Rituximab
7%
Lymph Node
7%
Progression-free Survival
7%
Cyclophosphamide
7%
Oncoprotein
7%
Germinal Center B Cells
7%
International Prognostic Index
7%
Lymphoid Tissue
7%
Ca2+
7%
Doxorubicin
7%
Patient Outcomes
7%
Malignant Tissue
7%
Medicine and Dentistry
Transient Receptor Potential Channel M4
100%
Transient Receptor Potential Channel
100%
B Cell
100%
Diffuse Large B-Cell Lymphoma
100%
Overall Survival
21%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
14%
Germinal Center
14%
Protein Expression
14%
Multivariate Analysis
7%
Doxorubicin
7%
Oncology
7%
International Prognostic Index
7%
Human Tissue
7%
Vincristine
7%
Lymphatic Tissue
7%
Lactate Dehydrogenase
7%
Oncoprotein
7%
Progression Free Survival
7%
Prednisone
7%
Tonsil
7%
Ion Channel
7%
Lymph Node
7%
Cyclophosphamide
7%
Isotopes of Calcium
7%
Calcium Ion
7%
Rituximab
7%
Immunology and Microbiology
Receptor Potential
100%
B Cell
100%
Overall Survival
15%
Protein Expression
10%
Germinal Center
10%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
10%
Progression Free Survival
5%
Tonsil
5%
Cyclophosphamide
5%
Rituximab
5%
Human Tissue
5%
Lymph Node
5%
Prednisone
5%
Lymphoid Tissue
5%